Assessment of pharmacokinetic changes of meropenem during therapy in septic critically ill patients

BMC Pharmacology and Toxicology

Volumn 15, Issue 1, 2014, Pages

  Goncalves Pereira, João ^a,b   Silva, Nuno Elvas ^c   Mateus, André ^c   Pinho, Catarina ^c   Povoa, Pedro ^a,b  

^a HOSPITAL DE SÃO FRANCISCO XAVIER   (Portugal)

^b UNIVERSIDADE NOVA DE LISBOA   (Portugal)

^c UNIVERSITY OF LISBON   (Portugal)

Author keywords

lactam antibiotics; Intensive care unit; Meropenem; Pharmacokinetics;

Indexed keywords

CREATININE; MEROPENEM; ANTIINFECTIVE AGENT; THIENAMYCIN DERIVATIVE;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CRITICALLY ILL PATIENT; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HUMAN; MALE; MIDDLE AGED; SEPSIS; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; TREATMENT DURATION; VERY ELDERLY; BLOOD; CLINICAL TRIAL; CRITICAL ILLNESS; METABOLISM;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CRITICAL ILLNESS; FEMALE; HUMANS; MALE; MIDDLE AGED; SEPSIS; THIENAMYCINS;

EID: 84906930024     PISSN: None     EISSN: 20506511     Source Type: Journal    
DOI: 10.1186/2050-6511-15-21     Document Type: Article

References (36)

1. Zhanel GG, Wiebe R, Dilay L, Thomson K, Rubinstein E, Hoban DJ, Noreddin AM, Karlowsky JA: Comparative review of the carbapenems. Drugs 2007, 67:1027-1052.
2. Pea F, Viale P: Bench-to-bedside review: appropriate antibiotic therapy in severe sepsis and septic shock-does the dose matter? Crit Care 2009, 13:214.
3. Roberts JA, Lipman J: Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Clin Pharmacokinet 2006, 45:755-773.
4. Goncalves-Pereira J, Povoa P: Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of beta-lactams. Crit Care 2011, 15:R206.
5. Sime FB, Roberts MS, Peake SL, Lipman J, Roberts JA: Does beta-lactam pharmacokinetic variability in critically Ill patients justify therapeutic drug monitoring? a systematic review. Ann Intensive Care 2012, 2:35.
6. Triginer C, Izquierdo I, Fernandez R, Rello J, Torrent J, Benito S, Net A: Gentamicin volume of distribution in critically ill septic patients. Intensive Care Med 1990, 16:303-306.
7. Le Gall JR, Lemeshow S, Saulnier F: A new simplified acute physiology score (SAPS II) based on a European/North American multicenter study. JAMA 1993, 270:2957-2963.
8. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, Reinhart CK, Suter PM, Thijs LG: The SOFA (Sepsis-related organ failure assessment) score to describe organ dysfunction/failure: on behalf of the working group on sepsis-related problems of the European society of intensive care medicine. Intensive Care Med 1996, 22:707-710.
9. Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40:373-383.
10. Roberts JA, Kirkpatrick CM, Roberts MS, Robertson TA, Dalley AJ, Lipman J: Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother 2009, 64:142-150.
11. Jaruratanasirikul S, Sriwiriyajan S, Punyo J: Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection. Antimicrob Agents Chemother 2005, 49:1337-1339.
12. de Stoppelaar F, Stolk L, van Tiel F, Beysens A, van der Geest S, de Leeuw P: Meropenem pharmacokinetics and pharmacodynamics in patients with ventilator-associated pneumonia. J Antimicrob Chemother 2000, 46:150-151.
13. Fuster-Lluch O, Geronimo-Pardo M, Peyro-Garcia R, Lizan-Garcia M: Glomerular hyperfiltration and albuminuria in critically ill patients. Anaesth Intensive Care 2008, 36:674-680.
14. Baptista JP, Udy AA, Sousa E, Pimentel J, Wang L, Roberts JA, Lipman J: A comparison of estimates of glomerular filtration in critically ill patients with augmented renal clearance. Crit Care 2011, 15:R139.
15. Udy AA, Baptista JP, Lim NL, Joynt GM, Jarrett P, Wockner L, Boots RJ, Lipman J: Augmented renal clearance in the ICU: results of a multicenter observational study of renal function in critically Ill patients with normal plasma creatinine concentrations*. Crit Care Med 2014, 42:520-527.
16. Kitzes-Cohen R, Farin D, Piva G, De Myttenaere-Bursztein SA: Pharmacokinetics and pharmacodynamics of meropenem in critically ill patients. Int J Antimicrob Agents 2002, 19:105-110.
17. Casu GS, Hites M, Jacobs F, Cotton F, Wolff F, Beumier M, De Backer D, Vincent JL, Taccone FS: Can changes in renal function predict variations in beta-lactam concentrations in septic patients? Int J Antimicrob Agents 2013, 42:422-428.
18. Lovering AM, Vickery CJ, Watkin DS, Leaper D, McMullin CM, White LO, Reeves DS, MacGowan AP: The pharmacokinetics of meropenem in surgical patients with moderate or severe infections. J Antimicrob Chemother 1995, 36:165-172.
19. Binder L, Schworer H, Hoppe S, Streit F, Neumann S, Beckmann A, Wachter R, Oellerich M, Walson PD: Pharmacokinetics of meropenem in critically ill patients with severe infections. Ther Drug Monit 2013, 35:63-70.
20. Delattre IK, Musuamba FT, Verbeeck RK, Dugernier T, Spapen H, Laterre PF, Wittebole X, Cumps J, Taccone FS, Vincent JL, Jacobs F, Wallemacq PE: Empirical models for dosage optimization of four beta-lactams in critically ill septic patients based on therapeutic drug monitoring of amikacin. Clin Biochem 2010, 43:589-598.
21. Sakka SG, Glauner AK, Bulitta JB, Kinzig-Schippers M, Pfister W, Drusano GL, Sorgel F: Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial. Antimicrob Agents Chemother 2007, 51:3304-3310.
22. Nduka OO, Parrillo JE: The pathophysiology of septic shock. Crit Care Clin 2009, 25:677-702. vii.
23. Taccone FS, Laterre PF, Dugernier T, Spapen H, Delattre I, Witebolle X, De Backer D, Layeux B, Wallemacq P, Vincent JL, Jacobs F: Insufficient beta-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care 2010, 14:R126.
24. Lipman J, Wallis SC, Boots RJ: Cefepime versus cefpirome: the importance of creatinine clearance. Anesth Analg 2003, 97:1149-1154.
25. Carlier M, De Waele JJ: Identifying patients at risk for augmented renal clearance in the ICU-limitations and challenges. Crit Care 2013, 17:130.
26. Andes D, Anon J, Jacobs MR, Craig WA: Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of respiratory tract infections. Clin Lab Med 2004, 24:477-502.
27. McKinnon PS, Paladino JA, Schentag JJ: Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T > MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents 2008, 31:345-351.
28. Hayashi Y, Lipman J, Udy AA, Ng M, McWhinney B, Ungerer J, Lust K, Roberts JA: Beta-Lactam therapeutic drug monitoring in the critically ill: optimising drug exposure in patients with fluctuating renal function and hypoalbuminaemia. Int J Antimicrob Agents 2012, 41:162-166.
29. Nicolau DP: Pharmacodynamic optimization of beta-lactams in the patient care setting. Crit Care 2008, 12(4):S2.
30. Kasiakou SK, Sermaides GJ, Michalopoulos A, Soteriades ES, Falagas ME: Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials. Lancet Infect Dis 2005, 5:581-589.
31. Dulhunty JM, Roberts JA, Davis JS, Webb SA, Bellomo R, Gomersall C, Shirwadkar C, Eastwood GM, Myburgh J, Paterson DL, Lipman J: Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial. Clin Infect Dis 2012, 56:236-244.
32. Chytra I, Stepan M, Benes J, Pelnar P, Zidkova A, Bergerova T, Pradl R, Kasal E: Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial. Crit Care 2012, 16:R113.
33. Roberts JA, Webb S, Paterson D, Ho KM, Lipman J: A systematic review on clinical benefits of continuous administration of beta-lactam antibiotics. Crit Care Med 2009, 37:2071-2078.
34. Goncalves-Pereira J, Oliveira BS, Janeiro S, Estilita J, Monteiro C, Salgueiro A, Vieira A, Gouveia J, Paulino C, Bento L, Povoa P: Continuous infusion of piperacillin/tazobactam in septic critically ill patients-a multicenter propensity matched analysis. PLoS One 2012, 7:e49845.
35. Carlier M, Carrette S, Roberts JA, Stove V, Verstraete AG, Hoste E, Decruyenaere J, Depuydt P, Lipman J, Wallis SC, De Weale JJ: Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used? Crit Care 2013, 17:R84.
36. Goncalves-Pereira J, Paiva JA: Dose modulation: a new concept of antibiotic therapy in the critically ill patient? J Crit Care 2013, 28:341-346.